Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAZE Maze Therapeutics

Market Closed 10-09 16:00:00 EDT

27.11

+1.23

+4.75%

盘后27.11

+0.000.00%

19:30 EDT

High27.19	Low25.88	Vol670.93K
Open25.88	D1 Closing25.88	Amplitude5.06%
Mkt Cap1.50B	Tradable Cap1.01B	Total Shares55.25M
T/O17.99M	T/O Rate1.80%	Tradable Shares37.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":27.11,"timestamp":1791576000000,"preClose":25.88,"halted":0,"volume":670925,"hourTrading":{"tag":"盘后","latestPrice":27.11,"preClose":27.11,"latestTime":"19:30 EDT","volume":5678,"amount":153932.02,"timestamp":1791588606417,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.047527047913446696,"floatShares":37250300,"shares":55248700,"eps":-2.517242,"marketStatus":"Market Closed","change":1.23,"latestTime":"10-09 16:00:00 EDT","open":25.88,"high":27.19,"low":25.88,"amount":17986920.241725,"amplitude":0.050618,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.517242,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":25.88,"preHourTrading":{"tag":"盘前","latestPrice":25.9,"preClose":25.88,"latestTime":"08:40 EDT","volume":114,"amount":2932.41003,"timestamp":1791549646118,"change":0.02,"changeRate":0.000773,"amplitude":0.083076},"postHourTrading":{"tag":"盘后","latestPrice":27.11,"preClose":27.11,"latestTime":"19:30 EDT","volume":5678,"amount":153932.02,"timestamp":1791588606417,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9239380409051559,"impliedVol":1.6439,"impliedVolPercentile":0.9402},"requestUrl":"/m/hq/s/MAZE/wiki","defaultTab":"wiki","newsList":[{"id":"2673063956","title":"Maze Therapeutics to Present Phase 2 Horizon Data for Mze829 in APOL1-Mediated Kidney Disease at ASN Kidney Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063956?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:07","pubTimestamp":1791317269,"startTime":"0","endTime":"0","summary":"Maze Therapeutics to present Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease at ASN Kidney Week 2026Maze Therapeutics flagged upcoming presentations on its kidney pipeline at ASN Kidn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL5d8pBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","IE00BQXX3C00.GBP","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","BCDF","NDAQ","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4007","LU2210150020.SGD","MAZE","IE00BQXX3F31.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672764185","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $202,920.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2672764185","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672764185?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:07","pubTimestamp":1790885254,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $202,920.75Maze Therapeutics CSBO Atul Dandekar exercised stock options for 7,500 shares at USD 10.42 on Sept. 29, 2026.He so","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL40cPjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $202,920.75","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488852","title":"Maze Therapeutics Rises After Citi Initiates with 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488852","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669488852?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:16","pubTimestamp":1790162183,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises after Citi initiates with 'buy'** Shares of biotech firm Maze TherapeuticsMAZE.Orise 1.5% to $28.8 premarket** Brokerage Citi initiates coverage with \"buy\" and a $50 PT, a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669104282","title":"Maze Therapeutics initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669104282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669104282?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:20","pubTimestamp":1790155214,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $50 price target The firm sees the company’s APOL1-mediated kidney diseas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669712668","title":"Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2669712668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669712668?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:50","pubTimestamp":1790095800,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc.  is currently at $27.23, up $4.84 or 21.62%--Would be highest close since Aug. 28, 2026, when it closed at $27.44--On pace for largest percent increase since Sept. 11, 2025, when it rose 54.81%--Snaps a five day losing streak--Up 2.48% month-to-date--Down 34.27% year-to-date--Down 47.47% from its all-time closing high of $51.84 on March 12, 2026--Up 9.45% from 52 weeks ago , when it closed at $24.88--Down 47.47% from its 52-week closing high of $51.84 on March 12, 2026--Up 21.62% from its 52-week closing low of $22.39 on Sept. 21, 2026--Traded as high as $29.40; highest intraday level since Aug. 26, 2026, when it hit $30.40--Up 31.31% at today's intraday high; largest intraday percent increase since Sept. 11, 2025, when it rose as much as 59.18%All data as of 12:44:05 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412656","title":"Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412656?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:47","pubTimestamp":1790095620,"startTime":"0","endTime":"0","summary":"Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","IE0002141913.USD","IBB","LU1778281490.HKD","BBH","BK4532","LU2456880835.USD","LU1815336091.USD","SGXZ57979304.SGD","PBE","XBI","LU1585245621.USD","IE00B894F039.SGD","IE00BJT1NW94.SGD","GNMX","LU2089984988.USD","LU2462157665.USD","LU2236285917.USD","VRTX","IE00B2B36J28.USD","LU1430594728.SGD","LU2362541513.USD","TBXU","VERX","BK4588","BK4567","LU0058720904.USD","MAZE","LU2324357040.USD","LU0289739699.SGD","LU0234570918.USD","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","IBBQ","IE0009355771.USD","LU0432979614.USD","LU0889565916.HKD","LU1093756168.USD","LU1069344957.HKD","LU1674673428.USD","LU0079474960.USD","BK4585","BK4023","LU0256863811.USD","LU1035775433.USD","LU2237438978.USD","IDNA","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377654","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377654","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377654?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:21","pubTimestamp":1788898887,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of 9,705 common shares for $254,543Harold Bernstein, President, R&D & CMO, sold 9,705 shares of Maze Therapeutics common stock on Sep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL3v02SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664801180","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2664801180","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664801180?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:24","pubTimestamp":1788467093,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein sells 16,141 common shares worth $425,392.65Harold Bernstein, President, R&D & CMO, reported a same-day exercise and sale in Maze Therapeutics","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL66dvcM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815092","title":"Maze Therapeutics to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815092","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815092?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354981/0/en/maze-therapeutics-to-participate-in-three-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885024","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885024","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885024?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:33","pubTimestamp":1788215589,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $206,823.75Maze Therapeutics CSBO Atul Dandekar sold 7,500 common shares on Aug. 28, 2026 at USD 27.58.The sale followed the exerci","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLJqTrc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778685","title":"Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778685?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:33","pubTimestamp":1787808780,"startTime":"0","endTime":"0","summary":"GENEVA, Aug. 27, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA  , a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update.Key Highlights-- Expanded U.S. commercial capabilities and reach through the build-out of. the Company's commercial organization, continued development of its. customer pipeline, and a channel partnership with Vibra Healthcare.-- Compelling real-world evidence from a two-year, multi-site program. -- Advanced its European reimbursement strategy with first patient. enrollment in SwissNeuroRehab and launch of the REACT-AVC study in. -- Expanded the clinical application of the platform through support for a. University of Pittsburgh study pairing spinal cord stimulation with. -- Completed organizational simplification, including the disposal of. non-neurology legacy operations, resulting in a focused organization and. -- Received CHF 4.0 million under a CHF 8.0 million ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660324524","title":"Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660324524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660324524?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:46","pubTimestamp":1786999574,"startTime":"0","endTime":"0","summary":"Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statementMaze Therapeutics director Paula A. Johnson filed an initial Form 3 on Aug. 17, 2026.Disclaimer:This news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL78z2DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660328084","title":"Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660328084","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660328084?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:18","pubTimestamp":1786997890,"startTime":"0","endTime":"0","summary":"Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directorsMaze Therapeutics named Paula Johnson and Sophie Kornowski to its board of directors.Johnson is president of Wellesley Coll","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL87kkJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712190","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712190","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712190?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:58","pubTimestamp":1786741080,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 445,522 common sharesMaze Therapeutics President, R&D and CMO Harold Bernstein sold 16,142 common shares on Aug. 13 at USD 27.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3LPRJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614160","title":"Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614160","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659614160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:49","pubTimestamp":1786654155,"startTime":"0","endTime":"0","summary":"Maze Therapeutics adds Paula Johnson, Sophie Kornowski to boardMaze Therapeutics appointed Paula Johnson and Sophie Kornowski to its board.Johnson is president of Wellesley College, a cardiologist, an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7LTtBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561818.USD","BK4534","LU2129689431.USD","LU0964807845.USD","BCDF","LU1732800096.USD","JDOC","LU1244550494.USD","SGXZ80539844.SGD","IXJ","LU0820561909.HKD","MEDX","JNJ","LU0345769128.USD","NDAQ","RXL","LU0820562030.AUD","BMED","IE00BJT1NW94.SGD","LU1066051811.HKD","TRUH","IYH","IE00BSNM7G36.USD","LU2456880835.USD","LU0787776722.HKD","LU0689472784.USD","LU1043141123.HKD","XLV","LU0985320562.USD","MAZE","PJP","IHE","IE00BGHQF631.EUR","FTXH","IE00BKPKM429.USD","FHLC","LU0320765646.SGD","LU0689626769.HKD","VHT","LU1778281490.HKD","IE00BVYPNW00.USD","LU1894683348.USD","BK4585","IE000SO60NU8.SGD","LU0345770993.USD","LU1221951046.USD","LU2112291526.USD","GDOC","LU2471134523.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659351160","title":"Maze Therapeutics Announces Appointments to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2659351160","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659351160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:42","pubTimestamp":1786653745,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUABH5JRC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659675701","title":"CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2659675701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659675701?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:22","pubTimestamp":1786652530,"startTime":"0","endTime":"0","summary":"CAMP4 Therapeutics Q2 loss per share misses estimates on non-cash derivative chargeOverviewUS biopharmaceutical developer's Q2 loss per share missed analyst expectationsNet loss widened due to non-cas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","BK4139","CAMP","ELOX","MAZE","BK4007","ABEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713511","title":"Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659713511?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:00","pubTimestamp":1786600849,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has disclosed a new risk, in the Regulation category. Maze Therapeutics, Inc. faces a material risk that future liti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-threaten-maze-therapeutics-funding-reputation-and-path-to-commercialization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legal-and-regulatory-risks-threaten-maze-therapeutics-funding-reputation-and-path-to-commercialization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659823201","title":"Belite Bio Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659823201","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659823201?lang=en_us&edition=fundamental","pubTime":"2026-08-13 09:55","pubTimestamp":1786586157,"startTime":"0","endTime":"0","summary":"Belite Bio Q2 net loss widens on higher expensesOverviewUS retinal disease drug developer's Q2 net loss widened as R&D and SG&A expenses increasedFDA accepted NDA for tinlarebant with Priority Review ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A01Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELOX","BLTE","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974286","title":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974286?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:40","pubTimestamp":1786534824,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Maze Therapeutics, Inc....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","FFTY","LFSC","XLV","IMNM","BK4139","TVTX","LU0029874061.USD","BK4137","BK4581","BK4585","BK4588","HCSG","LABU","LU0128526141.USD","MAZE","XBI","BK4563"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mazetx.com;ir.mazetx.com","stockEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1029},{"period":"3month","weight":-0.1132},{"period":"6month","weight":0.0157},{"period":"1year","weight":-0.0574},{"period":"ytd","weight":-0.3456}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction